Background and Purpose-We sought to explore the safety and efficacy of the new TREVO stent-like retriever in consecutive patients with acute stroke. Methods-We conducted a prospective, single-center study of 60 patients (mean age, 71.3 years; male 47%) with stroke lasting Ͻ8 hours in the anterior circulation (nϭ54) or Ͻ12 hours in the vertebrobasilar circulation (nϭ6) treated if CT perfusion/CT angiography confirmed a large artery occlusion, ruled out a malignant profile, or showed target mismatch if symptoms Ͼ4.5 hours. Successful recanalization (Thrombolysis In Cerebral Infarction 2b-3), good outcome (modified Rankin Scale score 0 -2) and mortality at Day 90, device-related complications, and symptomatic hemorrhage (parenchymal hematoma Type 1 or parenchymal hematoma Type 2 and National Institutes of Health Stroke Scale score increment Ն4 points) were prospectively assessed. Results-Median (interquartile range) National Institutes of Health Stroke Scale score on admission was 18 (12-22). The median (interquartile range) time from stroke onset to groin puncture was 210 (173-296) minutes. Successful revascularization was obtained in 44 (73.3%) of the cases when only the TREVO device was used and in 52 (86.7%) when other devices or additional intra-arterial tissue-type plasminogen activator were also required. The median time (interquartile range) of the procedure was 80 (45-114) minutes. Good outcome was achieved in 27 (45%) of the patients and the mortality rate was 28.3%. Seven patients (11.7%) presented a symptomatic intracranial hemorrhage. No other major complications were detected. Conclusions-The TREVO device was reasonably safe and effective in patients with severe stroke. These results support further investigation of the TREVO device in multicentric registries and randomized clinical trials. (Stroke. 2012;43:00-00.)
T he clinical efficacy of endovascular treatment in acute ischemic stroke has not been proven in randomized clinical trials. Meanwhile, several neurothrombectomy devices have shown widely varying rates of successful recanalization and/or harmful effects. 1 This study reports the first consecutive large series of patients with acute stroke treated with the new TREVO stent-like retriever ( Figure) .
Methods
From January to December 2010, 60 consecutive patients with acute stroke were treated by board-certified neuroangioradiologists using the TREVO stent-like retriever (Concentric Medical Inc, Mountain View, CA) as the unique device (nϭ49) or followed afterward by other devices (Solitaire, nϭ5; Merci, nϭ3; and Solitaire and Merci, nϭ3) or intra-arterial recombinant tissue-type plasminogen activator (nϭ1) because the TREVO device was unable to reopen the occluded vessel.
Clinical criteria included strokes lasting Ͻ8 hours in the anterior circulation or Ͻ12 hours in the vertebrobasilar circulation. Thirtythree patients (55%) received intravenous recombinant tissue-type plasminogen activator. All study participants had a CT perfusion/CT angiography that confirmed an artery occlusion proximal to M2, or a basilar occlusion, and ruled out a malignant profile as previously reported. 2 In patients with symptoms lasting Ͼ4.5 hours (nϭ19), the presence of mismatch was also required (online-only Data Supplement; http://stroke.ahajournals.org). All procedures were carried out without general anesthesia except in 3 patients with extreme agitation or hemodynamic and respiratory function instability.
Outcome Measures
Successful recanalization was defined as a Thrombolysis In Cerebral Infarction score of 2b or 3. Good clinical outcome was defined as a modified Rankin Scale score Յ2 at Day 90. Treatment-related complications were prospectively assessed and serious bleeding was defined as parenchymal hematomas Type I or Type II on CT scan associated with at least 4 points increase in the National Institutes of Health Stroke Scale score at 36 hours of treatment. Mortality at Day 90 was also registered.
Results
The main characteristics of the population are shown in Table  1 . The median (interquartile range) time from stroke onset to arterial puncture was 210 (173-296) minutes and 302 (243-391) minutes from stroke onset to successful recanalization, which was achieved in 73.3% of patients treated only with the TREVO. Thrombolysis In Cerebral Infarction 2b to 3 and Thrombolysis In Cerebral Infarction 2 to 3 were reached by 86.7% and 93% of patients, respectively, when additional devices or intraarterial tissue-type plasminogen activator were required. The median (interquartile range) time of the procedure (groin puncture to recanalization) was 80 (45-114) minutes.
Median (interquartile range) National Institutes of Health Stroke Scale score at baseline was 18 (12-22). Good outcome was achieved by 27 (45%) patients; there were 17 (28%) deaths, 7 (12%) serious bleedings, 1 carotid dissection before the TREVO device was deployed, and 1 symptomatic distal embolization that was clinically resolved at discharge. The main outcome measures of previous reperfusion studies are shown in Table 2 .
Discussion
To our knowledge, this is the first large prospective study reporting the main clinical effects of the TREVO device administered to consecutive patients with acute stroke treated according to predefined clinical and radiological criteria. The current study found a successful recanalization rate of 73.3% and that 45% of the treated patients had reached a good outcome at 3 months despite the high severity of stroke on admission (median National Institutes of Health Stroke Scale score of 18) and the protracted time delay to recanalization (5 hours). These encouraging results compare well with previous studies of endovascular therapy, [5] [6] [7] [8] [9] [10] and argue that the systematic use of advanced brain imaging seems to contribute to a better selection of the candidates to receive reperfusion therapies. 2 In addition, 95% of our cases were done without intubation during the procedure, which may also have affected outcome. The main limitations of the study were the lack of randomization and inclusion of a control group and that additional devices were used in 11 patients in which the TREVO device was unable to reanalyze the occluded vessel. However, these results may be of help to design future randomized studies of the TREVO device in acute stroke.
Conclusions
The TREVO device was reasonably safe and effective in patients with severe stroke managed according to predefined clinical criteria and assisted by the use of advanced brain imaging in the treatment decisions, although 18.3% of the patients may require the use of additional devices for successful recanalization. The value of this new device deserves further formal investigation in larger multicentric registries and randomized clinical trials.
Sources of Funding
Multimodal CT-assisted thrombolysis and systematic access to ET were possible through a pilot program granted by the Servei Català de Salut (Health Department of Catalonia, Catalonia, Spain). In patients admitted > 4.5 h of stroke onset (n=13), or in wake-up strokes (n=6), CTP and CTA were performed before treatment onset and the patients were considered eligible to receive ET when a target mismatch and a proximal occlusion were present and there was not a malignant profile. Age is not considered an exclusion criterion for intravenous tPA and ET is indicated in patients under 85 years old.
All the patients are admitted to our stroke Unit. Daily NIHSS evaluation is performed by neurologist specialized in stroke with current NIHSS certification and modified Rankin scale is assessed at 3 months by programmed visit or telephone contact.
Follow-up CT scan is performed within 24h after thrombolysis or when clinical worsening of at least 4 points in the NIHSS score occurred.
Brain imaging
CT scanning was obtained on a 64-row scanner. For CTP, serial CT was performed with a rapid bolus injection of contrast material and four adjacent 7.2mm thick sections were obtained per second for 40 seconds. Anatomic coverage was adjusted to the level of the basal ganglia when anterior circulation infarct was suspected, parallel and superior to the orbital roof. In posterior circulation infarct, the anatomical imaging reference used to position the dynamic perfusion studies was the internal auditory canal. CTA with maximum intensity projection (MIP) was used to assess location of the occlusion and cerebral blood volume (CBV), cerebral blood flow (CBF) and time to peak (TTP) maps were calculated using a commercially available semi-automated perfusion analysis software (Siemens) based on the maximum slope model of perfusion.
Maximum slope of the time attenuation curves (TAC) were used to calculate CBF, and CBV values were calculated from the maximum enhancement ratio.
Infarct core was segmented based on a CBV threshold of 0.6 relative to the contralateral white matter, 1 and ischemic penumbra was segmented based on a TTP threshold of 6 seconds for identification of critically hypoperfused tissue. In patients with basilar artery occlusions lasting >4.5 hour, magnetic resonance with DWI was used to rule out patients with severe ADC map abnormalities.
Device and and revascularisation procedure
The study was approved by the local ethics committee and informed written consent was obtained from the patients or their relatives. An 8F femoral guiding catheter with distal balloon for temporary flow occlusion was used whenever possible, otherwise a conventional 6F guiding catheter was used. In particularly tortuous vessels a 4.3 to 5.2 F coaxial distal access catheter was used. A 0.014-inch microwire was used to advance along the artery until a 0.18 micro catheter could be located distally to the thrombus. The TREVO was placed at the site of the thrombus, maintaining it open for at least 3 minutes. We always used continuous aspiration from the guider catheter and flow arrest in the cases where the balloon was used while the device was being removed. Unfractionated heparin was administrated in continuous perfusion at 500 unit/ hour and was stopped at the end of the procedure.
revascularization rate of 76%. In those cases in which Trevo was not able to reopen the vessel, Solitaire and/or Merci were used, again with a total number of three attempts with each of them. In our protocol, we never use GP2b3a
antagonists.
If the patient had a tandem occlusion of the proximal ICA, then angioplasty and stenting followed by distal mechanical thrombectomy were performed in the ICA. Eight hundred milligrams of lysine salicilate is administered previous to stent deployment followed by 300 mg of clopidogrel orally as early as possible.
